Business Description
AN2 Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US0373261058
Description
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8253.46 | |||||
| Equity-to-Asset | 0.9 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -78.5 | |||||
| 3-Year EPS without NRI Growth Rate | -41.5 | |||||
| 3-Year FCF Growth Rate | -80.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.94 | |||||
| 9-Day RSI | 24.36 | |||||
| 14-Day RSI | 24.99 | |||||
| 6-1 Month Momentum % | -77.38 | |||||
| 12-1 Month Momentum % | -60.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.87 | |||||
| Quick Ratio | 7.87 | |||||
| Cash Ratio | 7.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28.4 | |||||
| Shareholder Yield % | -118.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -61.15 | |||||
| ROA % | -55.31 | |||||
| ROIC % | -473.61 | |||||
| ROCE % | -65.78 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.54 | |||||
| Price-to-Tangible-Book | 0.54 | |||||
| EV-to-EBIT | 0.34 | |||||
| EV-to-EBITDA | 0.34 | |||||
| EV-to-FCF | 0.45 | |||||
| Price-to-Net-Current-Asset-Value | 0.7 | |||||
| Price-to-Net-Cash | 0.73 | |||||
| Earnings Yield (Greenblatt) % | 294.12 | |||||
| FCF Yield % | -78.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AN2 Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.77 | ||
| Beta | 0 | ||
| Volatility % | 144.84 | ||
| 14-Day RSI | 24.99 | ||
| 14-Day ATR ($) | 0.228246 | ||
| 20-Day SMA ($) | 2.8295 | ||
| 12-1 Month Momentum % | -60.37 | ||
| 52-Week Range ($) | 2.28 - 22.22 | ||
| Shares Outstanding (Mil) | 29.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AN2 Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AN2 Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
AN2 Therapeutics Inc Frequently Asked Questions
What is AN2 Therapeutics Inc(ANTX)'s stock price today?
The current price of ANTX is $2.28. The 52 week high of ANTX is $22.22 and 52 week low is $2.28.
When is next earnings date of AN2 Therapeutics Inc(ANTX)?
The next earnings date of AN2 Therapeutics Inc(ANTX) is 2024-05-10 Est..
Does AN2 Therapeutics Inc(ANTX) pay dividends? If so, how much?
AN2 Therapeutics Inc(ANTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers